Seeking Alpha

Sarepta Therapeutics (SRPT +8%) moves up on the back of on a positive article in Seeking Alpha...

Sarepta Therapeutics (SRPT +8%) moves up on the back of on a positive article in Seeking Alpha today, saying the stock looks "ridiculously overvalued" at current levels. Contributor Sean Anderson notes a number of potential catalysts to move the stock higher, but most significant is how little attention the stock currently gets on the Street, which could quickly change if of it's eteplirsen, a potential blockbuster treatment for Duchenne's disease, to receive early approval.
Comments (4)
  • ari5000
    , contributor
    Comments (366) | Send Message
     
    does whoever wrote this knows what "overvalued" means?
    5 Nov 2012, 02:34 PM Reply Like
  • upster51
    , contributor
    Comments (7) | Send Message
     
    oops-- they meant 'ridcul;ously undervaluled' .. lol
    5 Nov 2012, 02:38 PM Reply Like
  • Asherp20
    , contributor
    Comments (15) | Send Message
     
    I think you meant to write undervalued.
    5 Nov 2012, 03:05 PM Reply Like
  • sstrand1
    , contributor
    Comments (240) | Send Message
     
    wow how does something that blatant get by review b 4 going out to the investment community? and then where is the author issuing an apology and correction??? helllooooo??
    6 Nov 2012, 09:17 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector